Biofrontera Inc.

BFRI Nasdaq SEC CIK 1858685
Follow Biofrontera Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $9.1M +29.8% vs same quarter last year
Net income −$6.4M +3.4% vs same quarter last year
EPS, diluted −$0.42 +32.3% vs same quarter last year
Operating cash flow −$1.4M +62.5% vs same quarter last year
Revenue by quarter
$12.6M
$8.6M
$9M
$7M
$17.1M
$10.1M
$12M
$9.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$40M−$20M$0$20M$40M$60MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$41.7M−$10.5M
FY24$37.3M−$17.8M
FY23$34.1M−$20.1M
FY22$28.7M−$640K
FY21$24M−$37.7M
FY20$18.8M−$11M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−200%−150%−100%−50%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−27.2%−25.3%
FY24−46.1%−47.6%
FY23−66.6%−59.1%
FY22−64.8%−2.2%
FY21−104.8%−156.9%
FY20−51%−58.3%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$13.4M
FY24−$10.3M
FY23−$24.9M
FY22−$16.2M
FY21-
FY20-
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Biofrontera
  • Healthcare median
−200%−150%−100%−50%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearBiofronteraHealthcare median
FY25−25.3%−30.6%
FY24−47.6%−47%
FY23−59.1%−58%
FY22−2.2%−80.4%
FY21−156.9%−71.8%
FY20−58.3%−62.2%
FY19-−46.2%